Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| EUPAS38736 | Other Identifier | ENCEPP |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Biogen Netherlands B.V | UNKNOWN |
| Novartis Europharm Limited | UNKNOWN |
| Merck Europe B.V. | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
Observational data have suggested no increased risk of adverse pregnancy outcomes associated with exposure to interferon-beta (IFNB) before or during pregnancy. After the emergence of these data, the European Medicines Agency approved a label change for IFNB in September 2019, stating that use of IFNB during pregnancy may be considered, if clinically needed. However, limited data on pregnancies exposed in the 2nd and 3rd trimesters were observed.
INFORM is a secondary use of data drug utilisation study (DUS) to determine late pregnancy exposure (i.e. during the 2nd and 3rd trimester) to IFNB in Finland and Sweden, which will inform whether the number of exposed pregnancies is adequate to conduct a cohort study on adverse pregnancy outcomes, with a focus on late pregnancy exposure.
The number of pregnancies will be initially reported three years after the revised label implementation (September 2019) and will include data on pregnancies from 1996 in Finland and from 2005 in Sweden up through 31 December 2022. If the number of pregnancies is deemed adequate for conducting the cohort study on adverse pregnancy outcomes, this DUS will be finalised with the drug utilisation data accrued up through 31 December 2022. If the number of pregnancies until 31 December 2022 is deemed inadequate, this study may be continued and the primary and secondary objectives may be examined five years after the revised label implementation, including pregnancies until 31 December 2024.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Pregnancies exposed to IFNB only | With dispensed IFNB, no other MS disease modifying drugs (MSDMDs) during the pre-pregnancy period or during pregnancy |
| |
| Pregnancies unexposed to IFNB nor other MSDMDs | No dispensed IFNB nor any other MSDMDs during the pre-pregnancy period nor any time during pregnancy | ||
| Pregnancies exposed to IFNB (regardless of other MSDMDs) | With dispensed IFNB, regardless of other MS disease modifying drugs (MSDMDs) during the pre-pregnancy period or during pregnancy |
| |
| Pregnancies unexposed to IFNB (regardless of other MSDMDs) | No dispensed IFNB during the pre-pregnancy period nor any time during pregnancy, regardless of other MSDMDs Outcomes: |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Avonex (IFNβ-1-a, Biogen Netherlands B.V) | Drug | Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available. |
| Measure | Description | Time Frame |
|---|---|---|
| The number of pregnancies of women with MS, not allowing exposure to other MS Disease Modifying Drugs (MSDMDs) | Analysis groups: Pregnancies exposed to IFNB only group and Pregnancies unexposed to IFNB nor other MSDMDs group | Data recorded between 01 January 1996 - 31 December 2022 in Finland, and 01 July 2005 - 31 December 2022 in Sweden. |
| The level of precision for the risk of pre-defined adverse pregnancy outcomes in late pregnancy that can be obtained with the available number of exposed and unexposed pregnancies | Pre-defined adverse pregnancy outcomes:
Late pregnancy, i.e. the 2nd and 3rd trimester. | Data recorded between 01 January 1996 - 31 December 2022 in Finland, and 01 July 2005 - 31 December 2022 in Sweden. |
| The annual number of pregnancies of women with MS in the exposure groups | Analysis in Pregnancies exposed to IFNB only group. | Data recorded between 2015-2019 and 2020-2022. |
| Measure | Description | Time Frame |
|---|---|---|
| The number of pregnancies of women with MS in Finland and Sweden in exposure groups allowing exposure to other MSDMDs | Analysis groups: Pregnancies exposed to IFNB (regardless of other MSDMDs) group and Pregnancies unexposed to IFNB (regardless of other MSDMDs) group | Data recorded between 01 January 1996 - 31 December 2022 in Finland, and 01 July 2005 - 31 December 2022 in Sweden. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
- None.
Not provided
Not provided
Aggregate secondary data will be collected from the following national registers in Finland and Sweden.
FINLAND: Medical Birth Register (MBR-Fin), Care Register for Health Care, National Reimbursement Register/National Prescription Register, Register of Induced Abortions.
SWEDEN: Medical Birth Register (MBR-Swe), National Patient Register (NPR), Swedish Prescribed Drug Register (SPDR).
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Many locations | Multiple Locations | Finland | ||||
| Many locations |
No data will be shared
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Rebif (IFNβ-1-a, Merck Europe B.V.) | Drug | Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available. |
|
| Extavia (IFNβ-1-b, Novartis Europharm Limited) | Drug | Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available. |
|
| Betaseron (IFN-β-1-b, BAY86-5046, Bayer AG) | Drug | Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available. |
|
| Plegridy (Peg IFNβ-1-a, Biogen Netherlands B.V) | Drug | Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available. |
|
| MS disease modifying drugs (MSDMDs) | Drug | Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available. |
|
| The annual number of women with MS in childbearing age, and with dispensed IFNB | Data recorded between 2015 to 2022 in Finland and Sweden |
| Multiple Locations |
| Sweden |
| ID | Term |
|---|---|
| D009103 | Multiple Sclerosis |
| ID | Term |
|---|---|
| D020278 | Demyelinating Autoimmune Diseases, CNS |
| D020274 | Autoimmune Diseases of the Nervous System |
| D009422 | Nervous System Diseases |
| D003711 | Demyelinating Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000068556 | Interferon beta-1a |
| D000068576 | Interferon beta-1b |
| C428112 | peginterferon beta-1a |
| ID | Term |
|---|---|
| D016899 | Interferon-beta |
| D007370 | Interferon Type I |
| D007372 | Interferons |
| D016207 | Cytokines |
| D036341 | Intercellular Signaling Peptides and Proteins |
| D010455 | Peptides |
| D000602 | Amino Acids, Peptides, and Proteins |
| D011506 | Proteins |
| D001685 | Biological Factors |
Not provided
Not provided